{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T13:36:44Z","timestamp":1769693804470,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002345","name":"Eberhard Karls Universit\u00e4t T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002345","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Die Diagnose erblicher Netzhautdystrophien ist aufgrund der niedrigen Pr\u00e4valenz und der Variabilit\u00e4t der klinischen Pr\u00e4sentation schwierig. Eine bestm\u00f6glich gesicherte Diagnose ist f\u00fcr den Patienten f\u00fcr die Lebensplanung und die Abkl\u00e4rung der M\u00f6glichkeit einer fr\u00fchzeitigen zielgerichteten Therapie wesentlich.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Fragestellung<\/jats:title>\n                <jats:p>Ziel der vorliegenden Studie war es, ein besseres Bild des Patientenweges bis zur finalen Diagnosestellung nachzuzeichnen. Dies sollte dazu dienen, m\u00f6gliche Schwachstellen in der Diagnostik und Versorgung aufzudecken und Verbesserungspotenziale insbesondere im Hinblick auf die Nutzung genetischer Diagnostik aufzuzeigen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material und Methoden<\/jats:title>\n                <jats:p>Die Daten wurden mittels Umfrageb\u00f6gen und Online-Interviews von der Selbsthilfevereinigung PRO RETINA Deutschland e.\u202fV. unter Patienten mit erblichen Netzhautdystrophien erhoben. Daten wurden mittels deskriptiver Statistik ausgewertet.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Im Zeitraum vom 15.03. bis zum 22.04.2021 wurden 183 Umfrageb\u00f6gen ausgef\u00fcllt und 42\u00a0Online-Interviews durchgef\u00fchrt. Die Umfragepopulation bestand aus 48\u202f% weiblichen Teilnehmern, das Durchschnittsalter betrug 55\u00a0Jahre, erste Symptome traten im Schnitt im Alter von 22\u00a0Jahren auf. Von den ersten Symptomen bis zur finalen Diagnose vergingen etwa 14\u00a0Jahre. Lediglich 66\u202f% der Befragten gaben an, dass mindestens 1\u00a0Gentest bei Ihnen durchgef\u00fchrt wurde; weniger als die H\u00e4lfte (47\u202f%) erhielt eine humangenetische Beratung. Die \u00fcberwiegende Mehrheit (85\u202f%) w\u00fcrde eine Gentherapie erw\u00e4gen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerung<\/jats:title>\n                <jats:p>Aus der Patientenperspektive sind eine Verk\u00fcrzung des Diagnoseweges, das Angebot einer molekulargenetischen Diagnostik sowie einer humangenetischen Beratung wesentlich f\u00fcr die Verbesserung der Versorgung von Patienten mit erblichen Netzhautdystrophien.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00347-022-01602-w","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T13:10:00Z","timestamp":1647868200000},"page":"820-826","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Diagnostik erblicher Netzhautdystrophien. Stellenwert molekulargenetischer Diagnostik aus Patientenperspektive","Diagnosis of inherited retinal dystrophies. Relevance of molecular genetic testing from the patient\u2019s perspective"],"prefix":"10.1007","volume":"119","author":[{"given":"Ulrich","family":"Kellner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Bucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8132-911X","authenticated-orcid":false,"given":"Katarina","family":"Stingl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"1602_CR1","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00417-019-04280-8","volume":"257","author":"NM Bax","year":"2019","unstructured":"Bax\u00a0NM, Lambertus\u00a0S, Cremers\u00a0FPM et\u00a0al (2019) The absence of fundus abnormalities in Stargardt disease. Graefes Arch Clin Exp Ophthalmol 257:1147\u20131157. https:\/\/doi.org\/10.1007\/s00417-019-04280-8","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1602_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1055\/a-1386-5361","volume":"238","author":"HJ Bolz","year":"2021","unstructured":"Bolz\u00a0HJ (2021) Diagnostic analyses of retinal dystrophy genes: current status and perspective. Klin Monbl Augenheilkd 238:261\u2013266. https:\/\/doi.org\/10.1055\/a-1386-5361","journal-title":"Klin Monbl Augenheilkd"},{"key":"1602_CR3","first-page":"415","volume":"41","author":"HJ Bolz","year":"2020","unstructured":"Bolz\u00a0HJ, Kellner\u00a0U, Priglinger\u00a0S (2020) Gendiagnostik und -therapie in der Augenheilkunde. Z\u00a0Prakt Augenheilkd 41:415\u2013427","journal-title":"Z Prakt Augenheilkd"},{"key":"1602_CR4","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/ajmg.c.31835","volume":"184","author":"K Branham","year":"2020","unstructured":"Branham\u00a0K, Schlegel\u00a0D, Fahim\u00a0AT, Jayasundera\u00a0KT (2020) Genetic testing for inherited retinal degenerations: triumphs and tribulations. Am J Med Genet 184:571\u2013577. https:\/\/doi.org\/10.1002\/ajmg.c.31835","journal-title":"Am J Med Genet"},{"key":"1602_CR5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1001\/archopht.122.4.477","volume":"122","author":"N Congdon","year":"2004","unstructured":"Congdon\u00a0N, O\u2019Colmain\u00a0B, Klaver\u00a0CCW et\u00a0al (2004) Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122:477\u2013485. https:\/\/doi.org\/10.1001\/archopht.122.4.477","journal-title":"Arch Ophthalmol"},{"key":"1602_CR6","volume-title":"Erbliche Netzhaut\u2011, Aderhaut- und Sehbahnerkrankungen \u2013 S1 Leitlinie","author":"Deutsche Ophthalmologische Gesellschaft (DOG)","year":"2021","unstructured":"Deutsche Ophthalmologische Gesellschaft (DOG), Retinologischenschaft (RG), Berufsverbands der Augen\u00e4rzte Deutschlands e.\u202fV. (BVA) (2021) Erbliche Netzhaut\u2011, Aderhaut- und Sehbahnerkrankungen \u2013 S1 Leitlinie"},{"key":"1602_CR7","doi-asserted-by":"publisher","first-page":"5684","DOI":"10.3390\/ijms22115684","volume":"22","author":"A Dockery","year":"2021","unstructured":"Dockery\u00a0A, Whelan\u00a0L, Humphries\u00a0P, Farrar\u00a0GJ (2021) Next-generation sequencing applications for inherited retinal diseases. Int J Mol Sci 22:5684. https:\/\/doi.org\/10.3390\/ijms22115684","journal-title":"Int J Mol Sci."},{"key":"1602_CR8","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1073\/pnas.1913179117","volume":"117","author":"M Hanany","year":"2020","unstructured":"Hanany\u00a0M, Rivolta\u00a0C, Sharon\u00a0D (2020) Worldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases. Proc Natl Acad Sci U S\u00a0A 117:2710\u20132716. https:\/\/doi.org\/10.1073\/pnas.1913179117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1602_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/13816810.2021.1913610","author":"HRC Jeffery","year":"2021","unstructured":"Jeffery\u00a0HRC, Mukhtar\u00a0SA, McAllister\u00a0IL et al (2021) Inherited retinal diseases are the most common cause of blindness in the working-age population in Australia. Ophthalmic Genet. https:\/\/doi.org\/10.1080\/13816810.2021.1913610","journal-title":"Ophthalmic Genet"},{"key":"1602_CR10","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/aos.14218","volume":"98","author":"JP Holtan","year":"2020","unstructured":"Holtan\u00a0JP, Selmer\u00a0KK, Heimdal\u00a0KR, Bragad\u00f3ttir\u00a0R (2020) Inherited retinal disease in Norway\u2014a\u00a0characterization of current clinical and genetic knowledge. Acta Ophthalmol 98:286\u2013295. https:\/\/doi.org\/10.1111\/aos.14218","journal-title":"Acta Ophthalmol"},{"key":"1602_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1055\/a-1118-3705","volume":"237","author":"U Kellner","year":"2020","unstructured":"Kellner\u00a0U, Kellner\u00a0S, Saleh\u00a0M et\u00a0al (2020) Heredit\u00e4re Netzhautdystrophien: Kombination ophthalmologischer Methoden zur Optimierung des Readout. Klin Monatsbl Augenheilkd 237:275\u2013287. https:\/\/doi.org\/10.1055\/a-1118-3705","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"1602_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1055\/s-0031-1280461","volume":"229","author":"U Kellner","year":"2012","unstructured":"Kellner\u00a0U, Renner\u00a0A, Herbst\u00a0S et\u00a0al (2012) Heredit\u00e4re Netzhautdystrophien. Klin Monatsbl Augenheilkd 229:171\u2013196. https:\/\/doi.org\/10.1055\/s-0031-1280461","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"1602_CR13","doi-asserted-by":"publisher","first-page":"e004015","DOI":"10.1136\/bmjopen-2013-004015","volume":"4","author":"G Liew","year":"2014","unstructured":"Liew\u00a0G, Michaelides\u00a0M, Bunce\u00a0C (2014) A comparison of the causes of blindness certifications in England and Wales in working age adults (16\u201364\u00a0years), 1999\u20132000 with 2009\u20132010. Bmj Open 4:e4015. https:\/\/doi.org\/10.1136\/bmjopen-2013-004015","journal-title":"Bmj Open"},{"key":"1602_CR14","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1159\/000514540","volume":"64","author":"B Lorenz","year":"2021","unstructured":"Lorenz\u00a0B, Tavares\u00a0J, van den Born\u00a0LI et\u00a0al (2021) Current management of inherited retinal degeneration patients in Europe: results of a\u00a0multinational survey by the European vision institute clinical research network. Ophthalmic Res 64:622\u2013638. https:\/\/doi.org\/10.1159\/000514540","journal-title":"Ophthalmic Res"},{"key":"1602_CR15","first-page":"153","volume":"14","author":"B Puech","year":"1991","unstructured":"Puech\u00a0B, Kostrubiec\u00a0B, Hache\u00a0JC, Fran\u00e7ois\u00a0P (1991) Epidemiology and prevalence of hereditary retinal dystrophies in the Northern France. J\u00a0Fr Ophtalmol 14:153\u2013164","journal-title":"J Fr Ophtalmol"},{"key":"1602_CR16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/13816810.2020.1778736","volume":"41","author":"M Shah","year":"2020","unstructured":"Shah\u00a0M, Shanks\u00a0M, Packham\u00a0E et al (2020) Next generation sequencing using phenotype-based panels for genetic testing in inherited retinal diseases. Ophthalmic Genet 41:331\u2013337. https:\/\/doi.org\/10.1080\/13816810.2020.1778736","journal-title":"Ophthalmic Genet"},{"key":"1602_CR17","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1002\/humu.24064","volume":"41","author":"N Weisschuh","year":"2020","unstructured":"Weisschuh\u00a0N, Obermaier\u00a0CD, Battke\u00a0F et al (2020) Genetic architecture of inherited retinal degeneration in Germany: a large cohort study from a\u00a0single diagnostic center over a\u00a09-year period. Hum Mutat 41:1514\u20131527. https:\/\/doi.org\/10.1002\/humu.24064","journal-title":"Hum Mutat"},{"key":"1602_CR18","unstructured":"RetNet (2021) https:\/\/sph.uth.edu\/retnet\/sum-dis.htm. Zugegriffen: 30.10.2021"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-022-01602-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-022-01602-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-022-01602-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T11:36:24Z","timestamp":1660563384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-022-01602-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1602"],"URL":"https:\/\/doi.org\/10.1007\/s00347-022-01602-w","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,21]]},"assertion":[{"value":"3 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"U.\u00a0Kellner erhielt keinen finanziellen Ausgleich von der Novartis Pharma GmbH f\u00fcr die Unterst\u00fctzung bei der Dateninterpretation und der Manuskripterstellung. U.\u00a0K. erhielt finanzielle Kompensation f\u00fcr Beratert\u00e4tigkeiten bzw. Referentent\u00e4tigkeiten sowie Forschungsf\u00f6rderung von Bayer Vital GmbH, Heidelberg Engineering GmbH, Mylan Ltd., Novartis Pharma GmbH, Roche GmbH, Samsung GmbH. Er ist Gesellschafter der UDRBK GmbH, Vorsitzender der Vereinigung operierender Augen\u00e4rzte Nordrhein, Vorsitzender des Arbeitskreises klinischer Fragen und Mitglied des Wissenschaftlich-Medizinischen Beirats der PRO RETINA Deutschland e.\u202fV. und arbeitet aktiv in den Leitlinienkommissionen DOG\/BVA mit. S.\u00a0Jansen erhielt keinen finanziellen Ausgleich von der Novartis Pharma GmbH f\u00fcr die Unterst\u00fctzung bei der Dateninterpretation und der Manuskripterstellung. F.\u00a0Bucher ist Angestellte der Novartis Pharma GmbH. K.\u00a0Stingl erhielt keinen finanziellen Ausgleich von der Novartis Pharma GmbH f\u00fcr die Unterst\u00fctzung bei der Dateninterpretation und der Manuskripterstellung. K.\u00a0S. erhielt finanzielle Kompensation f\u00fcr Beratert\u00e4tigkeiten bzw. Referentent\u00e4tigkeiten sowie Forschungsf\u00f6rderung von EVICR.net, <i>Foundation Fighting Blindness<\/i>, Janssen-Cilag GmbH,<i> Kerstan Foundation, Lightning health<\/i>, Novartis Pharma GmbH, <i>Orphan disease center<\/i> (Pennsylvania), ProQR <i>Therapeutics N.\u00a0V.<\/i>, PRO RETINA Deutschland e.\u202fV., Santen GmbH, ViGeneron GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Diese Patientenumfrage wurde von PRO RETINA Deutschland e.\u202fV. durchgef\u00fchrt. Die Auswertung der Daten erfolgte durch die Firma IPSOS, Hamburg. Markos Schulte (CROLLL GmbH) lieferte Unterst\u00fctzung beim Medical Writing. F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. Diese Patientenumfrage bedurfte keiner Genehmigung durch eine Ethikkommission. Die Erhebung der Daten erfolgte unter Wahrung der geltenden Datenschutzgesetze.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}